Hanmi Pharm close to commercialize new once-month administration diabetes drug

Published: 2015-09-24 14:19:25

Updated: 2015-09-24 14:19:25

Possibility to develop the once-monthly administration for a new GLP-1 diabetes drug(efpeglenatide), developed by Hanmi Pharm, has been confirmed once again.

Hanmi Pharm(CEO Kwan-soon Lee) announced that the company has revealed 9 major research cases of new long-acting diabetes drugs, which are currently being developed, at the European Association for the Study of Diabetes(hereinafter referr...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.